The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity.

The present invention relates to an (amide amino alkane) metal compound represented by the formula (1): wherein M represents a metal atom;R1 represents a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms;R2 and R3 may be the same as, or different from each other, and each independently represents a linear or branched alkyl group having 1 to 3 carbon atoms, or R2 and R3 may form a substituted or unsubstituted 5- or 6-membered ring together with the nitrogen atom to which they are bound;Z represents a linear or branched alkylene group having 1 to 10 carbon atoms (a part of which may optionally form a ring); andn represents a number of the ligands, which is equal to the valence of the metal (M), and represents an integer of from 1 to 3; with the proviso that the metal compounds in which M is Li (Lithium), Be (Beryllium), Ge (Germanium) or Nd (Neodymium) are excluded;the metal compounds in which M is Mg (Magnesium) and R1 is methyl group are excluded;the metal compounds in which M is Zn (Zinc) and R1 is methyl group are excluded;the metal compounds in which M is Bi (Bismuth) and R1 is t-butyl group are excluded; andin cases where n is two or greater, two or more ligands may be the same as, or different from each other; and a method of producing a metal-containing thin film using the metal compound.

Disclosed is a spectrofluorimetrically detectable luminescent composition consisting essentially of at least one energy transfer acceptor lanthanide(III) complex having an emission spectrum maximum in the range from 300 to 2000 nanometers and a luminescence-enhancing amount of at least one energy transfer donor selected from the group consisting of a fluorophore, a lumiphore, an organic compound, a salt of an organic ion, a metal ion, a metal ion complex, or a combination thereof. Such energy transfer donor enhances the luminescence of at least one energy transfer acceptor lanthanide(III) complex, with the conditions that the emission spectrum of any energy transfer donor differs from that of its energy transfer acceptor lanthanide(III) complex; and such energy transfer donor can be dissolved to form a unitary solution in a solvent having an evaporation rate at least as great as that of water.

A coloring matter which exhibits excellent (ozone) gas resistance, high print density, low color rendering properties, low color saturation, and high-quality black hue when is recorded on a paper only for inkjet exclusive use, i.e., an azo compound represented by formula (1), a tautomer of the azo compound, or a salt of the azo compound or the tautomer; and an ink composition containing the coloring matter, particularly a black ink composition for inkjet recording applications.

It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.

Provided, amongst other things, are dyes of formula II: wherein R1, R2, R3 and R4 are independently H or alkyl, so long as one or more is alkyl, and salts of the compound of formula II. Methods of making, inks, surgical markers and methods of marking tissue and the like are further provided.

Disclosed herein is a GO-Gd-DTPA (gadolinium-diethylenetriamine pentaacetic-graphene oxide) complex, which is formed by an ester bond of graphene oxide (GO) and gadopentetic acid (Gd-DTPA). Since the GO-Gd-DTPA can stably exist in the body because it has high stability in water, it is expected that it can be effectively used as an MRI contrast agent.

The present disclosure provides a photoreactive synthetic regulator of protein function. The present disclosure further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present disclosure further provides methods of modulating protein function, involving use of light.

An organic compound has the following chemical structure: wherein R is different from R*; R and R* are independently hydrogen, halogen, nitro or methoxyl; and R1 is a C1-C6 alkyl or a phenyl group. A quaternary data storage device includes a bottom electrode, a top electrode, and the organic film layer sandwiched between the bottom electrode and the top electrode.

A hypoxia contrast medium including nitroimidazole-amino acid chelate with a positively charged radioactive nuclide, a preparation method and use thereof. The contrast medium can be used in imaging cerebral thrombosis, tumors or other diseases such as ulceration, thrombosis, and so on.

The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.

A method and apparatus for transporting syringes containing radioactive material. The apparatus includes a radiopharmaceutical pig having an inner chamber in which a sharps container can be secured. The sharps container has a housing and an attachable cap. The method includes assembling the radiopharmaceutical pig so that the chamber of the radiopharmaceutical pig contains the syringe in the sharps container housing. The radiopharmaceutical pig is disassembled, where upon the syringe is removed, discharged, and then replaced in the sharps container housing. The cap of the sharps container is affixed to the housing of the sharps container, thus enclosing the contaminated syringe therein. The radiopharmaceutical pig is assembled so that its chamber contains the sharps container and the syringe. The radiopharmaceutical pig is transported to a disposal area, where it is disassembled and the sharps container containing the syringe is placed in a particular disposal container.

A method for removing radioactive contaminants from a given surface. An acidic solution having a pH of less than 3.0, and preferably less than 1.5, of a complex substituted keto-amine, and a mixture of a saturated and unsaturated lower alcohol (e.g. isopropyl alcohol and propargyl alcohol), and concentrated acid is applied to a contaminated surface. The solution is left on said surface for a time sufficient to remove the radioactive contaminants into the acidic solution and then removed. The acidic solution containing the radioactive contaminants is preferably neuralized by an alkaline material to a pH of between 5.5 and 9.0. Removal of thorium contamination from railcars is one useful application of the invention. The method of the present invention has the effect of removing substantially all of the radioactive contaminants from a previously contaminated surface.

A preferred embodiment may generally be construed as providing a method for storing fissile material, such as spent nuclear fuel (SNF), and includes the steps of: providing a storage container configured to receive the fissile material therein; and applying a coating to a surface of the storage container. Preferably, the coating is formed, at least in part, of a neutron-absorbing material and is adapted to reduce neutron multiplication and/or provide a shielding of the fissile material received within the storage container. Systems also are provided.

A method for removing radioactive contaminants from a given surface. An aqueous solution having a wetting agent and a complex substituted keto-amine is provided. The solution is left on the surface for a time sufficient to remove the radioactive contaminants into the aqueous solution which is then removed. Depending on the type and condition of the surface, a concentrated acid may be added to the aqueous solution to aid in the contaminant removal process. In such a case, a pH of less than 3.0, and preferably less than 1.5 is maintained. If a concentrated acid is used, the acidic solution containing radioactive contaminants is preferably neutralized by an alkaline material to a pH of between 5.5 and 9.0. Removal of thorium contamination from railcars is one useful application of the invention. The method of the present invention has the effect of removing substantially all of the radioactive contaminants from a previously contaminated surface.

The present invention relates to a process to dissolve plutonium or a plutonium alloy, by placing it in contact with an aqueous dissolution mixture, wherein said dissolution mixture comprises nitric acid, a carboxylic acid with complexing properties with respect to plutonium, and a compound comprising at least one —NH2 radical such as urea. The invention also relates to a process to convert plutonium or a plutonium alloy into plutonium oxide and to manufacture nuclear fuel from said oxide.The invention particularly applies to the dismantling of plutonium contained in nuclear weapons with a view to its use in civilian nuclear reactors, particularly in the form of MOX fuel.

A method for removing a wide variety of radioactive contaminants from a contaminated surface sufficient for the surface to be classified as a low-level waste or as free release. Contaminated surfaces may be classified as Class C, Class B, Class A, or high-level radioactive wastes prior to treatment. An aqueous solution having a wetting agent and a complex substituted keto-amine is provided. The aqueous solution is left on the surface for a time sufficient to remove the radioactive contaminants into the aqueous solution which is then removed. Depending on the type and condition of the surface, an acid may be added to the aqueous solution to aid in the contaminant removal process. However, typical metals surfaces may often be treated effectively without the use of concentrated acids or with dilute concentrations of such acids. The method of the present invention has the effect of removing substantially all of the radioactive contaminants from a variety of previously contaminated surfaces.

This invention is provided for improvement of corrosion-resistant property of a crucible and for promotion of safety in a pyrochemical reprocessing method for the spent nuclear fuel. The spent nuclear fuel is dissolved in a molten salt placed in the crucible. In a pyrochemical reprocessing method, the nuclear fuel is deposited, and the crucible (2) is heated by induction heating. Cooling media (5, 6) are supplied to cool down, and a molten salt layer (7) is maintained by keeping balance between the heating and the cooling, and a solidified salt layer (8) is formed on inner wall surface of the crucible.

A radioactive substance decontamination method and apparatus which decontaminates a metal member contaminated by radioactive substance in a short period of time. This apparatus has (1) multiple reducing decontamination tanks having different radiation control values; (2) a carrier for immersing the metal member into the multiple reducing decontamination tanks and a washing tank; (3) a tube for transferring into the second reducing decontamination tank the reducing decontamination agent in the first reducing decontamination tank; (4) a reducing agent decomposer for decomposing a component contained in the reducing decontamination agent of the reducing decontamination tank where the radiation control value is the highest out of the reducing decontamination tanks connected by the tube; and (5) a washing tank for washing the reducing decontamination agent deposited on the decontaminated metal member.

The invention provides a method of separating uranium from at least fission products in irradiated nuclear fuel, said method comprising reacting said irradiated nuclear fuel with a solution of ammonium fluoride in hydrogen fluoride fluorinating said reacted irradiated nuclear fuel to form a volatile uranium fluoride compound and separating said volatile uranium fluoride compound from involatile fission products. The invention thus provides a reprocessing scheme for irradiated nuclear fuel. The method is also capable of reacting, and breaking down Zircaloy cladding and stainless steel assembly components. Thus, whole fuel elements may be dissolved as one thereby simplifying procedures over conventional Purex processes.

In a chemical decontamination method of chemically decontaminating radioactive nuclides from a metallic material, oxalic acid and hydrazine are injected as a reductive decontaminating agent into water that is in contact with the metallic material. Injection of the hydrazine is stopped after a cation resin arranged in a circulation line connected to the metallic material breaks, and at least the oxalic acid and the hydrazine in the reductive decontaminating agent are decomposed using a decomposing catalyst.

A method and apparatus for transporting syringes containing radioactive material. The apparatus includes a radiopharmaceutical pig having an inner chamber in which a sharps container can be secured. The sharps container has a housing and an attachable cap. The method includes assembling the radiopharmaceutical pig so that the chamber of the radiopharmaceutical pig contains the syringe in the sharps container housing. The radiopharmaceutical pig is disassembled, where upon the syringe is removed, discharged, and then replaced in the sharps container housing. The cap of the sharps container is affixed to the housing of the sharps container, thus enclosing the contaminated syringe therein. The radiopharmaceutical pig is assembled so that its chamber contains the sharps container and the syringe. The radiopharmaceutical pig is transported to a disposal area, where it is disassembled and the sharps container containing the syringe is placed in a particular disposal container.

A method and apparatus for transporting syringes containing radioactive material. The apparatus includes a radiopharmaceutical pig having an inner chamber in which a sharps container can be secured. The sharps container has a housing and an attachable cap. The method includes assembling the radiopharmaceutical pig so that the chamber of the radiopharmaceutical pig contains the syringe in the sharps container housing. The radiopharmaceutical pig is disassembled, where upon the syringe is removed, discharged, and then replaced in the sharps container housing. The cap of the sharps container is affixed to the housing of the sharps container, thus enclosing the contaminated syringe therein. The radiopharmaceutical pig is assembled so that its chamber contains the sharps container and the syringe. The radiopharmaceutical pig is transported to a disposal area, where it is disassembled and the sharps container containing the syringe is placed in a particular disposal container.

A method for chemically decontaminating radioactive material. The method includes reducing-dissolving step for setting surface of radioactive material in contact with reducing decontamination liquid including mono-carboxylic acid and di-carboxylic acid as dissolvent; and oxidizing-dissolving step for setting the surface of the radioactive material in contact with oxidizing decontamination liquid including oxidizer. The method may include repeated pairs of steps, each pair including the reducing-dissolving step and the oxidizing-dissolving step. The mono-carboxylic acid may include formic acid, and the di-carboxylic acid includes oxalic acid. The oxidizer may be ozone, permanganic acid or permanganate.

A method for cooling a heat source, a method for preventing chemical interaction between a vessel and a cooling composition therein, and a cooling system. The method for cooling employs a containment vessel with an oxidizable interior wall. The interior wall is oxidized to form an oxide barrier layer thereon, the cooling composition is monitored for excess oxidizing agent, and a reducing agent is provided to eliminate excess oxidation. The method for preventing chemical interaction between a vessel and a cooling composition involves introducing a sufficient quantity of a reactant which is reactive with the vessel in order to produce a barrier layer therein that is non-reactive with the cooling composition. The cooling system includes a containment vessel with oxidizing agent and reducing agent delivery conveyances and a monitor of oxidation and reduction states so that proper maintenance of a vessel wall oxidation layer occurs.

Decontamination of nuclear facilities is necessary to reduce the radiation field during normal operations and decommissioning of complex equipment. In this invention, we discuss gel and foam based diphosphonic acid (HEDPA) chemical solutions that are unique in that these solutions can be applied at room temperature; provide protection to the base metal for continued applications of the equipment; and reduce the final waste form production to one step. The HEDPA gels and foams are formulated with benign chemicals, including various solvents, such as ionic liquids and reducing and complexing agents such as hydroxamic acids, and formaldehyde sulfoxylate. Gel and foam based HEDPA processes allow for decontamination of difficult to reach surfaces that are unmanageable with traditional aqueous process methods. Also, the gel and foam components are optimized to maximize the dissolution rate and assist in the chemical transformation of the gel and foam to a stable waste form.

A variable-voltage variable-frequency power source for an electric motor that drives a re-circulation pump for a boiling water nuclear reactor. The power source has a semiconductor electric power converter and a speed controller for controlling the semiconductor electric power converter. When a part of the semiconductor electric power converter comes into an inoperative state, that part is electrically disconnected, and the variable-voltage variable-frequency power source temporarily stops outputting power, thereby idling the re-circulation pump. Thereafter, the power source re-starts outputting power before the re-circulation pump completely stops. Thus, the re-circulation pump keeps operating, without stopping.

A working apparatus has: a working equipment for doing works on a structure; an operation mechanism adapted to actively move the working equipment relative to the structure; and an adhering/traveling module coupled to the operation mechanism and adapted to adhere to the structure so as to have the weight of the working apparatus borne by the structure and travel/move on the structure for positioning. With this arrangement, the working apparatus can perform accurate positioning operations in a narrow environment and complex scanning operations by means of various pieces of the working equipment such as inspection sensors, and can secure a large working area within a short period of time and reduce the overall working hours.

A system and method for a self-charging battery cell are provided in which beta emissions from a Strontium-90 source are obtained by a sensor device and converted into electric energy. In embodiments, a scintillation device is used to intake emissions from a Strontium-90 source, and consequently emit a light or plurality of light flashes. A sensor device, e.g., a photodiode, is utilized to convert the light or plurality of light flashes into electric voltage, current and/or energy.

Illustrative embodiments provide a nuclear fission reactor, a vented nuclear fission fuel module, methods therefor and a vented nuclear fission fuel module system.

A method for recovery of residual actinide element from chloride molten salts that are formed after electro-refining and/or electro-winning of a spent nuclear fuel and include actinide elements and rare-earth elements is provided. The method comprises conducting electrolysis using a liquid cadmium cathode (LCC) in the chloride molten salt that is formed after electro-refining and/or electro-winning of a spent nuclear fuel and contains rare-earth elements and actinide elements; electro-depositing the actinide elements contained in the chloride molten salt on the LCC in order to reduce a concentration of the actinide elements; and adding a CdCl2 oxidant to the chloride molten salt containing the LCC-metal alloy in order to oxidize the rare-earth elements co-deposited on the LCC, thereby forming the rare-earth chlorides in the chloride molten salt.

Compositions are provided that include nuclear fuel. Methods for treating nuclear fuel are provided which can include exposing the fuel to a carbonate-peroxide solution. Methods can also include exposing the fuel to an ammonium solution. Methods for acquiring molybdenum from a uranium comprising material are provided.

A method for design of a fuel assembly for nuclear reactors, including structural components made from zirconium alloy: the mean uniaxial tensile or compressive stress to which the components are subjected during the assembly life is calculated, the zirconium alloy of which the components are made is selected according to the following criteria: those components subjected to an axial or transverse compressive stress of between −10 et −20 MPa are made from an alloy with a content of Sn between Sn=(=0.025σ−0.25)% and Sn=−0.05σ%: those components subjected to such a stress of between 0 et −10 MPa are made from an alloy the Sn content of which is between Sn=traces and Sn=(0.05σ+1)%: those components subjected to such a stress of between 0 and +10 MPa are made from an alloy the Sn content of which is between Sn=0.05% and Sn=(0.07σ+1)%: and those components subjected to such a stress of between +10 and +20 MPa are made from an alloy the content of SN of which is between 0.05% and 1.70%. A fuel assembly made according to the method.

Compositions are provided that include nuclear fuel. Methods for treating nuclear fuel are provided which can include exposing the fuel to a carbonate-peroxide solution. Methods can also include exposing the fuel to an ammonium solution. Methods for acquiring molybdenum from a uranium comprising material are provided.

Illustrative embodiments provide a nuclear fission reactor, a vented nuclear fission fuel module, methods therefor and a vented nuclear fission fuel module system.

A reactor installation tool and method for installing a reactor unit in a reactor tube. A reactor installation tool including a movable assembly and a fixed assembly linked together such that the movable assembly can be adjusted relative to the fixed assembly. The movable assembly including a reactor sleeve attachment means for releasably securing a reactor sleeve loaded with a reactor unit to the tool. The fixed assembly including an expandable clamping unit for releasably securing the tool to a reactor tube. A reactor unit can be installed in the reactor tube by adjusting the movable assembly to extract the reactor unit from the reactor sleeve as the fixed assembly is rigidly secured to the reactor tube. The fixed assembly can be released from the reactor tube and the reactor installation tool can be removed from the reactor tube.

A method for measuring the neutron flux in the core of a nuclear reactor, the method including several steps recurrently performed at instants separated by a period, the method comprising at each given instant the following steps: acquiring a total signal by a cobalt neutron detector placed inside the core of the reactor; assessing a calibration factor representative of the delayed component of the total signal due to the presence of cobalt 60 in the neutron detector; assessing a corrected signal representative of the neutron flux at the detector from the total signal and from the calibration factor; assessing a slope representative of the time-dependent change of the calibration factor between the preceding instant and the given instant; the calibration factor at the given instant being assessed as a function of the calibration factor assessed at the preceding instant, of the slope, and of the time period separating the given instant from the preceding instant.

Disclosed is a process of stabilizing spent filter material that comprises mixing the filter media with a city media to produce a composition having a moisture content that is sufficiently low to retard microbial growth. The composition comprises spent filter media and a dry material, and preferably comprises diatomaceous earth. Soil is treated by adding the composition as a top dressing, soil amendment, or the like.

A fine motion control rod drive mechanism handling apparatus attaches a fine motion control rod drive mechanism having a control rod drive mechanism body, a spool piece, a motor bracket and a motor unit to a reactor pressure vessel, and detaches it from the reactor pressure vessel. The fine motion control rod drive mechanism handling apparatus is provided with a bolt wrench assembly, a motor unit attachment mounted to the bolt wrench assembly, for meshing a first gear of a first gear coupling on a spool piece side with a second gear of a second gear coupling on a motor unit side, and a rotation mechanism mounted to the bolt wrench assembly, for rotating the motor unit attachment.

Disclosed embodiments include methods of assembling a vented nuclear fission fuel module. Given by way of non-limiting example and not of limitation, an illustrative method of assembling a vented nuclear fission fuel module includes receiving a nuclear fission fuel element capable of generating a gaseous fission product. A valve body is coupled to the nuclear fission fuel element, and the valve body defines a plenum therein for receiving the gaseous fission product. A valve is disposed in communication with the plenum for controllably venting the gaseous fission product from the plenum. A flexible diaphragm is coupled to the valve for moving the valve. A cap is mounted on the valve, and a manipulator extendable to the cap for manipulating the cap is received.

Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide.

The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

The present invention relates to isolation of whey proteins and the preparation of a whey product and a whey isolate. In particular the present invention relates to the isolation of a β-lactoglobulin product and the isolation of an α-enriched whey protein isolate from whey obtained from an animal. The α-enriched whey protein isolate provided by the present invention is besides from being low in β-lactoglobulin also high in α-lactalbumin and immunoglobulin G.

Methods for treating fatty liver disease, e.g., hepatic steatosis, using peptide fragments of the C-terminal end of glucagon-like peptide-1 (GLP-1), e.g., GLP-1(28-36).

Provided are a support for affinity chromatography which has excellent alkali resistance, and a method for isolating immunoglobulin. A support for affinity chromatography, containing an immobilized protein ligand represented by the following formula (1): R—R2 (1) wherein R represents a polypeptide consisting of 4 to 30 amino acid residues that contains an amino acid sequence represented by ATK or ASK; and R2 represents a polypeptide consisting of 50 to 500 amino acid residues containing an immunoglobulin-binding domain consisting of an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2, the partial sequence thereof, or an amino acid sequence having 70% or more identity to these sequences; with the proviso that a terminus at which R2 binds to R is C-terminus or N-terminus of the immunoglobulin-binding domain.

In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.

The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.

The present invention relates to methods for forming dicarba bridges in organic compounds. This involves the use of a pair of complementary metathesisable groups on the organic compound, and subjecting the compound to cross-metathesis under microwave radiation conditions. In an alternative, the compounds contain a turn-inducing group between the pair of cross-metathesisable groups to facilitate the cross-metathesis.